But certainly, I think long-term, it can be a very, very strong opportunity. A third issue may relate to sotagliflozin, which Viatris opted to license from its developer Lexicon Therapeutics ...
StockStory.org on MSN1d
Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals StocksThe end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...
Hosted on MSN1d
What's in the Cards for Viatris Stock This Q4 Earnings?Viatris VTRS, a global healthcare company, is scheduled to report fourth-quarter and full-year 2024 results on Feb. 27, 2025.
Analysts' consensus rating on Viatris stock is cautious, with a "Hold" overall rating. Out of seven analysts covering the stock, one advises a "Strong Buy," four suggest a "Hold," one recommends ...
Shares of Viatris Inc. VTRS dropped 0.68% to $11.72 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.11% to 5,842.91 ...
Shares of Viatris Inc. VTRS shed 0.33% to $11.96 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.16% to 5,918.25 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback